Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC for XMT-1522 in Human Plasma.
XMT-1522, an investigational antibody-drug conjugate (ADC) being developed by Mersana Therapeutics and Takeda, represents the first Dolaflexin®-based, cleavable ADC with a high drug-antibody ratio (DAR). Although the drug showed promise in Phase I clinical development, earlier this year Mersana and Takeda agreed to prioritize resources to focus on the advancement of another ADC, XMT-1536, a first-in-class ADC candidate targeting NaPi2b, ending the co-development collaboration for XMT-1522.
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
Pregabalin, (S)-3-(aminomethyl)-5-methylhexanoic acid, is an analog of the neurotransmitter gamma amino butyric acid (GABA), used for the treatment of peripheral and central neuropathic pain in adults and as adjunctive therapy for refractory partial seizures. The aim of this study is to develop a sensitive, specific, robust, and rapid LC-MS/MS method, using a simple extraction procedure with no interference from the matrix and with a short run time.
Liquid biopsy is a sampling method for biomarker analysis that minimizes invasiveness, allows routine sampling, and is associated with circulating cell-free DNA. In this webinar, we talk about the benefits and challenges of sequencing cell-free DNA.
Frontage’s experienced staff and state-of-the-art instrumentation deliver data you can trust. Count on Frontage Laboratories for reliability. From method development or transfer and validation to sample analysis and reporting, Frontage’s bioanalytical team has earned a reputation for consistent and high-quality delivery, project after project. Our bioanalytical expertise extends to combined small and large molecules such as protein, antibody, antibody-drug conjugates as well as biomarker analysis for small molecule drug candidates.